Brief: Ocular Therapeutix™ Investor Day To Highlight US FDA Alignment On Axpaxli™ NDA With Submission Planned For Fourth Quarter 2026
Today 14:21
BRIEF-Ocular Therapeutix™ Investor Day To Highlight US FDA Alignment On Axpaxli™ NDA With Submission Planned For Fourth Quarter 2026 June 17 (Reuters) - Ocular Therapeutix Inc OCUL.O:
OCULAR THERAPEUTIX™ INVESTOR DAY TO HIGHLIGHT U.S. FDA ALIGNMENT ON AXPAXLI™ NDA WITH SUBMISSION PLANNED FOR FOURTH QUARTER 2026
OCULAR THERAPEUTIX INC - SOL-R EFFICACY DATA NO LONGER PART OF AXPAXLI NDA SUBMISSION PLAN
OCULAR THERAPEUTIX - SOL-R TRIAL TO REMAIN MASKED THROUGH WEEK 96; TOPLINE RESULTS EXPECTED Q1 2028
OCULAR THERAPEUTIX - TO CONDUCT INTERIM SOL-R SAFETY ANALYSIS IN Q4 2026
OCULAR THERAPEUTIX INC - PLANS TO SUBMIT ITS NDA UNDER 505(B)(2) PATHWAY, WITH POTENTIAL TO ACCELERATE REVIEW TIMELINE BY UP TO 60 DAYS
Source text: ID:nGNXfjxfr
Further company coverage: OCUL.O
((Reuters.Briefs@thomsonreuters.com;))